Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
europe blog main
4
×
europe top stories
life sciences
national blog main
boston blog main
boston top stories
clinical trials
fda
national top stories
national
san francisco blog main
san francisco top stories
abaloparatide
abbvie
alkermes
allergan
amgen
arena pharmaceuticals
biopharma
boston
boulder/denver blog main
boulder/denver top stories
buprenorphine
cancer
cardiovascular disease
cariprazine
colorectal cancer
deals
detroit blog main
detroit top stories
duchenne
eisai
eli lilly
europe
european commission
felipe jain
indiana blog main
indiana top stories
jess fiedorowicz
What
medicine
4
×
drug
fda
approval
marketing
weight
won
alkermes
amgen
amgen’s
antipsychotic
benefits
betting
billion
biopharma
cancer
carries
caveats
commonly
deal
designed
developed
duchenne
effect
eisai
europe
european
favor
flags
gain
gene
heart
higher
historic
incidence
lorcaserin
loss
market
nod
offer
Language
unset
Current search:
biotech
×
" europe blog main "
×
medicine
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning